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13.09.008Abstract Induced pluripotent stem (iPS) cells can be generated from mouse or human ﬁbroblasts
by exogenous expression of four factors, Oct4, Sox2, Klf4 and c-Myc, and hold great potential for
transplantation therapies and regenerative medicine. However, use of retroviral vectors during iPS
cell generation has limited the technique’s clinical application due to the potential risks resulting
from genome integration of transgenes, including insertional mutations and altered differentiation
potentials of the target cells, which may lead to pathologies such as tumorigenesis. Here we review
recent progress in generating safer transgene-free or integration-free iPS cells, including the use of
non-integrating vectors, excision of vectors after integration, DNA-free delivery of factors and
chemical induction of pluripotency.Introduction
In 2006, induced pluripotent stem (iPS) cells were ﬁrst
generated from mouse ﬁbroblasts by forced expression of four
protein factors, Oct4, Klf4, Sox2 and c-Myc, mediated by
retrovirus [1]. Human cells can also be reprogrammed using
the same set of four factors [2] or Oct4, Sox2, Lin28 and
Nanog [3]. iPS cells were proven to exhibit pluripotency at lev-
els similar to embryonic stem (ES) cells. Thus patient-speciﬁc.
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jing Institute of Genomics, Chinese Apluripotent stem cells can be produced without the problems
of immune rejection for disease models, transplantation thera-
pies and regenerative medicine.
However, iPS technology is complicated by the potential
risks posed by genome-integrating viruses. The transgenes
are randomly but permanently integrated into the host genome
at multiple sites together with viral vector backbone. The
expression of exogenous transgenes is silenced after repro-
gramming is achieved, and this silencing is indispensable for
maintaining pluripotency. Such genome-integrating viral vec-
tors can produce insertional mutations which may inﬂuence
differentiation potential, or even result in tumorigenesis due
to reactivation of the c-Myc oncogene [4]. Reprogramming
methods that utilize viral vectors are therefore judged too risky
to be used in clinical therapies. Recently, several approaches
have been developed to generate safer transgene-free or
integration-free iPS cells, as listed in Table 1.cademy of Sciences and Genetics Society of China. Production and hosting
Table 1 Summary of iPS cell induction strategies
Species Vector or method Reprogramming eﬃciency Year Ref
Mouse Retrovirus 104 2006 [1]
Non-integrating vector
Mouse Adenovirus 106–105 2008 [5]
Human Adenovirus 2 · 106 2009 [6]
Human Sendai virus 103–102 2009 [7]
Mouse Expression plasmids 106–2 · 105* 2008 [8]
Human Episomal vectors 3–6 · 106 2009 [9]
Human Episomal plasmid vectors 1 · 105–3 · 104 2011 [10]
Human Minicircle vector 5 · 105 2010 [11]
Mouse Liposomal magnetofection 4 · 104 2012 [12]
Deletion after integration
Human Retroviral transfection plus Cre recombinase – 2012 [13]
Mouse/human piggyBac transposon 3 · 104 2009 [14]
Mouse/human piggyBac transposon – 2009 [15]
DNA-free delivery
Mouse Fusion protein transduction 6 · 105* 2009 [16]
Human Fusion protein transduction 105* 2009 [17]
Mouse/human mRNA transduction 1 · 102* 2010 [18]
Chemical induction
Mouse Small molecule compounds 2 · 103 2013 [20]
Note: *Repeated transfections were conducted.
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A series of non-integrating vectors, including viral vectors and
non-viral vectors, have been used successfully for generating
iPS cells.
Adenovirus
Replication-incompetent adenoviral vectors were used to gen-
erate iPS cells from mouse [5] and human [6] somatic cells.
These vectors allow for transient expression of exogenous
genes without integration into the host genome, although with
a low efﬁciency compared to integrating vectors [5].
Sendai virus
Sendai virus (SeV) is thought to be able to replace retrovirus,
since it is also an RNA virus and can be easily removed by
antibody-mediated negative selection. SeV replicates in the
form of single-stranded RNA in the cytoplasm of infected
cells, therefore DNA would be neither produced nor integrated
into the host genome during transduction. Thus it has been
used as a safe vector in the ﬁeld of gene therapy. SeV-derived
transgenes were expressed three days after transduction. The
resulting iPS cells were generated with a high efﬁciency [7],
and the SeV vectors were then diluted by cell passages [7].
Expression plasmids
Several classes of vectors have been used as viral substitutes to
produce transgene-free iPS cells without integration, and
expression plasmids were among the ﬁrst to be investigated.
Repeated transfection of the plasmids containing the four
Yamanaka factors into mouse embryonic ﬁbroblasts (MEF)
resulted in iPS cells without integration, although with a much
lower efﬁciency than viral vectors [8].Episomal vectors
Other types of non-integrating vectors were explored to intro-
duce reprogramming factors intomouse or human somatic cells.
For example, portions of the Epstein-Barr human herpesvirus
were used to create a vector that can be transfected without viral
packaging. The resulting extrachromosomal oriP/EBNA1 (Ep-
stein-Barr nuclear antigen-1) episomal vector also features a
drug selection mechanism for removing the vector from cells.
The oriP/EBNA1 vector undergoes stable extrachromosomal
replication only once per cell cycle, without integrating into
the host genome. However, efﬁciency for iPS generation using
episomal vector was very low (3–6 · 106) [9]. Okita et al. [10]
further improved the episomal vector by using p53 suppression
and non-transforming L-Myc instead of c-Myc, resulting in
markedly enhanced iPS generation (1 · 105–3 · 104).
Minicircle vector
Minicircle expression vectors (i.e., supercoiled DNA molecules
that lack a bacterial origin of replication) have higher transfec-
tion efﬁciencies and longer-term transgene expression com-
pared to plasmids due to reduced silencing for exogenous
genes. A single minicircle vector containing four reprogram-
ming factors was introduced into human ES cells by nucleofec-
tion, and the minicircle plasmid backbone was then excised
and degraded using the PhiC31-based intramolecular recombi-
nation system [11].
Liposomal magnetofection
For liposomal magnetofection (LMF), cationic lipids mediate
the self-assembly of complexes containing plasmids and nano-
particles of superparamagnetic iron. These ‘‘CombiMag-
DNA’’ ternary complexes can be concentrated at cell surfaces
using a strong magnetic ﬁeld to transfect vectors into the
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cells achieved short reprogramming times of 8 days or less. In
addition, out of seven independently-generated iPS lines, two
iPS lines that had no integrated vector were produced [12].
Deletion after integration
Two systems have been applied to remove integrated trans-
genes from mouse or human iPS cells.
Cre-loxP system
Cre/loxP recombination was used to excise integrated trans-
genes from iPS cells. Human iPS cells were produced using a
single retroviral vector carrying OCT4, SOX2, KLF4 and
c-MYC linked via picornaviral 2A plasmids. This cassette
was removed by transfection of Cre recombinase after
reprogramming was achieved. However, residual vector se-
quences were left behind, therefore insertional mutations re-
main a risk [13].
piggyBac transposon
Another system used seamless excision of piggyBac (PB) trans-
posons to produce vector- and transgene-free mouse iPS cells.
Inverted terminal repeats derived from the PB transposon are
used to ﬂank a transgene with recognition sequences for a trans-
posase enzyme. Insertions and excisions can then be triggered by
regulated, transient expression of the transposase. The four fac-
tors were transfered into the PB transposon plasmid under the
transcriptional control of the tetO2 tetracycline/doxycycline
inducible promoter. MEF were transfected with circular PB
transposon plasmid together with a PB transposase expression
plasmid, and then maintained in the presence of doxycycline.
After complete reprogramming, excision of the piggyBac
vector and its induction factors from iPS cell lines was
achieved with a pulse of PB transposase expression. In 10
out of 11 subclone lines, the sequence at the transposon inte-
gration site reverted to wild type after vector excision [14,15].
DNA-free delivery
Proteins
Alternative methods to avoid introducing genetic modiﬁca-
tions include delivery of the reprogramming proteins or
mRNA directly into cells, rather than their expression from
DNA. These methods have been successfully demonstrated
but can be much more complicated to perform.
Togenerate recombinantproteins that canpenetrate and cross
the plasmamembraneof somatic cells, the carboxy termini of four
reprogramming factors were fused to a poly-arginine protein
transduction domain. After being added to the cell culture med-
ium, the recombinant transcription factors readily entered cells
within 6 h and could translocate to the nucleus. iPS cells were ob-
tained after four repeated protein transductions at 8 mg/ml with
1 mM valproic acid (VPA), a histone deacetylase inhibitor that
can signiﬁcantly improve reprogramming efﬁciency [16].
Similar protein transduction was also accomplished by Kim
et al. [17]. Human iPS cell-like colonies were established within8 weeks after six rounds of transduction using four reprogram-
ming factors fused with 9-arginine and myc tags. The resulting
induction efﬁciency was approximately twice as high as that
using viral transduction.
mRNAs
The use of synthetic RNAs for reprogramming was reported by
Warren et al. with surprisingly high reprogramming efﬁciencies
[18]. mRNAs including 30 and 50 untranslated regions were syn-
thesized via in vitro transcription. RNA transfection with a cat-
ionic vehicle into MEF and human somatic cells revealed a
high, dose–dependent cytotoxicity. Modiﬁed ribonucleotides
and phosphatase treatment, in conjunction with media supple-
mented with the interferon inhibitor B18R, were used to opti-
mize the synthetic mRNA approach and improve cell
viability. Maximal protein expression was observed 12–18 h
after transfection, followed by a rapid turnover that necessitates
subsequent daily transfections. A ﬁve-factor cocktail including
a modiﬁed LIN28 RNA produced reprogramming efﬁciencies
of 1.4%, much higher than using the virus-based approach
(104), and with a shorter time period (around 18 days) [18].
Chemical induction
Small molecules have advantages because they are non-immu-
nogenic, and can be more easily administered and standardized.
Moreover, their effects on inhibiting or activating speciﬁc pro-
teins are often reversible anddose–dependent. Smallmolecule li-
braries and combinations of compounds have been screened to
identify substitutes for transgenic DNA delivery. Initially, iPS
cells were generated from mouse ﬁbroblasts using a single gene,
Oct4,with a smallmolecule combination termed ‘‘VC6T’’ [VPA,
CHIR99021 (CHIR), 616452 and tranylcypromine] [19]. Next,
chemical substitutes for Oct4 were screened as supplements to
VC6T to obtain transgene-free iPS cells. In the Oct4 promoter-
driven GFP expression (OG) system, some GFP-positive clus-
ters were induced by VC6T plus forskolin (VC6TF), however
they lacked expression of Oct4 and Nanog, indicating incom-
plete reprogramming [20]. To identify the chemicals critical for
late reprogramming, a doxycycline (DOX)-inducible Oct4
expression system was used in which DOX was added only in
the ﬁrst 4–8 days. Several cAMP agonists including forskolin,
prostaglandin E2 and rolipram, and epigenetic modulators such
as 3-deazaneplanocin A (DZNep), 5-azacytidine, sodium buty-
rate and RG108 were identiﬁed [20]. Among all the candidates,
DZNep was proven to work well. DZNep was added 16 days
after treatment with VC6TF, followed by a day 28 switch to
2i-medium for dual inhibition (2i) of glycogen synthase kinase-
3 (GSK-3) and mitogen-activated protein kinase (MAPK) sig-
naling. The resulting chemically induced pluripotent stem cells
(CiPSCs) developed into colonies with ES-like properties. Efﬁ-
ciency can be boosted by a synthetic retinoic acid receptor li-
gand, TTNPB, for up to 0.2% cells induced [20].
DZNep is critical for activating endogenous Oct4. As an
S-adenosyl homocysteine (SAH) hydrolase inhibitor, DZNep
may repress the SAM-dependent cellular methylation process
and signiﬁcantly decrease DNA and H3K9 methylation at
the Oct4 promoter, which may contribute to Oct4 activation.
These ﬁndings indicate that appropriate combinations of
inducing chemicals and previously characterized drugs can
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clinical utility, bypassing nucleic acid manipulations and the
need to deploy protein factors.
Perspective
The efﬁciency and safety of generating and using iPS cells seem
to show a negative correlation, and thus clinical applications of
iPS technology await the validation of a mature protocol that
better balances these two important elements. Generation of
iPS cells by recombinant proteins is still worth considering for
clinical use due to its high safety, despite being quite expensive
and having very low efﬁciency. Recent reports point out that
activation of toll-like receptor-3 (TLR3) leads to epigenetic
modiﬁcation and facilitates nuclear reprogramming by the four
inducing factors [21]. Therefore, TLR3 manipulation may sup-
port nuclear reprogramming with amuch higher efﬁciency com-
pared tousing retrovirally encodedproteins alone.Additionally,
mRNA transduction was reported to have high efﬁciency, but
the rapid turnover of mRNA complicates this approach and
necessitates repeated, daily transfections. The newly reported
chemical induction method is promising for clinical use, owing
to its high safety and feasibility. Moreover, the chimeric mice
generated from CiPSCs were 100% viable and apparently
healthy, unlike those generated from retrovirus-induced iPS
cells. Chemical library screening for TLR3 activators could lead
to reﬁnements in theCiPSC induction cocktail and protocol that
further boost efﬁciency. Additional veriﬁcation of CiPSCs
including tetraploid complementation is needed to conﬁrm stem
cell function before its extensive application. Nonetheless, CiP-
SCs provide a new tool to study the mechanisms of reprogram-
ming thatmay lead tomore improvements in iPS cell production
and safety, and eventually powerful iPS cell therapeutics.
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